Table 2: Initiation and Treatment History (N = 200)
|
Variable |
Frequency |
Percentage |
Mean ± SD/median (IQR) |
|
WHO stage at initiation |
|
|
|
|
Stage I |
33 |
16.5 |
|
|
Stage II |
96 |
48 |
|
|
Stage III |
53 |
26.5 |
|
|
Stage IV |
18 |
9 |
|
|
Place of treatment initiation |
|
|
|
|
Same health facility |
197 |
98.5 |
|
|
Different health facility |
3 |
1.5 |
|
|
Median CD4 at initiation (cells/mm3) |
|
|
298 (158-416) |
|
Median First viral load in copies/ml (n = 181) |
|
|
210 (60-945) |
|
0-40 |
37 |
20.4 |
|
|
41-200 |
53 |
29.3 |
|
|
201-1000 |
46 |
25.4 |
|
|
>1000 |
45 |
24.9 |
|
|
Median Last viral load in copies/ml (n=11) |
|
|
300 (40-2419) |
|
0-40 |
4 |
36.4 |
|
|
41-200 |
1 |
9.1 |
|
|
201-1000 |
1 |
9.1 |
|
|
>1000 |
5 |
45.5 |
|
|
First-line treatment |
197 |
98.5 |
|
|
Second-line treatment |
3 |
1.5 |
|
|
Mean Number of doses per day |
|
|
1 ± 1 |
|
Reported side effects |
78 |
39 |
|
|
Dizziness |
29 |
37.2 |
|
|
Nausea |
22 |
28.2 |
|
|
Headaches |
23 |
29.5 |
|
|
Fatigue |
15 |
19.2 |
|
|
Skin rash |
2 |
2.5 |
|
|
Somnolence |
3 |
3.8 |
|
|
Insomnia |
11 |
14.1 |
|
|
Opportunistic infections |
25 |
12.5 |
|
|
Herpes Zoster |
11 |
44 |
|
|
Tuberculosis |
9 |
36 |
|
|
Oropharyngeal candidiasis |
4 |
16 |
|
|
Toxoplasmosis |
2 |
8 |
|
|
Other treatment |
29 |
14.5 |
|
|
Anti TB |
5 |
17.2 |
|
|
OCS |
6 |
20.7 |
|
|
Anti-hypertensives |
4 |
13.8 |
|
|
Anti-diabetics |
2 |
6.9 |
|
|
Iron supplements |
1 |
3.4 |
|
|
Traditional medication |
14 |
48.3 |
|